<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004175</url>
  </required_header>
  <id_info>
    <org_study_id>NU 98B1</org_study_id>
    <secondary_id>NU-98B1</secondary_id>
    <secondary_id>NCI-G99-1643</secondary_id>
    <nct_id>NCT00004175</nct_id>
  </id_info>
  <brief_title>Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer</brief_title>
  <official_title>Phase II Study of Taxotere, Doxorubicin and Cyclophosphamide (TAC) Primary Therapy in Stage III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining docetaxel, doxorubicin, and&#xD;
      cyclophosphamide in treating women who have previously untreated stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the clinical response rate to docetaxel, doxorubicin, and&#xD;
      cyclophosphamide as primary therapy in women with stage III breast cancer. II. Determine the&#xD;
      pathologic complete response rate to this treatment regimen in this patient population. III.&#xD;
      Assess the side effects and toxicity profile of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open label, multicenter study. Patients receive doxorubicin IV over 5-10&#xD;
      minutes followed by cyclophosphamide IV over 5-10 minutes and docetaxel IV over 1 hour.&#xD;
      Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Within 5 weeks following completion of chemotherapy, operable patients&#xD;
      achieving complete or partial response undergo mastectomy, segmental mastectomy, or&#xD;
      lumpectomy with nodal dissection. Patients with positive surgical tumor margins may undergo&#xD;
      an additional surgical procedure. Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed previously untreated,&#xD;
        stage III adenocarcinoma of the breast At least one bidimensionally and/or unidimensionally&#xD;
        measurable lesion No evidence of disease outside the breast or chest wall, except for&#xD;
        ipsilateral axillary lymph nodes Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified&#xD;
        Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic:&#xD;
        Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin&#xD;
        no greater than upper limit of normal (ULN) SGOT no greater than 3 times ULN Alkaline&#xD;
        phosphatase no greater than 5 times ULN No acute hepatitis Renal: Creatinine no greater&#xD;
        than 1.5 mg/dL No uncontrolled hypercalcemia Cardiovascular: No congestive heart failure&#xD;
        LVEF normal No angina pectoris No uncontrolled cardiac arrhythmias No other significant&#xD;
        heart disease No myocardial infarction within the past year No superior vena cava syndrome&#xD;
        No deep vein thrombosis requiring anticoagulant therapy Neurologic: No dementia No seizures&#xD;
        No concurrent grade 2 or greater peripheral neuropathy Other: No medical instability No&#xD;
        active infection No gastrointestinal bleeding No uncontrolled diabetes No psychological,&#xD;
        familial, sociological, or geographical conditions or other circumstances that would&#xD;
        preclude study No other malignancy within the past 5 years except curatively treated basal&#xD;
        cell skin cancer or carcinoma in situ of the cervix No history of hypersensitivity to&#xD;
        polysorbate 80 Not pregnant or nursing Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy for breast cancer&#xD;
        Chemotherapy: No prior chemotherapy for breast cancer Endocrine therapy: No prior hormonal&#xD;
        therapy for breast cancer No concurrent corticosteroids except for chronic&#xD;
        methylprednisolone or equivalent for more than 6 months duration at no more than 20 mg/day&#xD;
        Radiotherapy: Not specified Surgery: Not specified Other: At least 3 weeks since prior&#xD;
        investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J. Gradishar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Medical Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>March 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2004</study_first_posted>
  <disposition_first_submitted>July 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

